Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 5/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093178 | 0.86 | GLA (0.58) | GLANPSR1MDM2HTT | |
| SCHEMBL3103917 | 0.85 | GLA (0.66) | GLANPSR1 | |
| SCHEMBL16174918 | 0.84 | GLA (0.49) | GLANPSR1CES2EP300CTRB1 | |
| SCHEMBL9193771 | 0.84 | GLA (0.69) | GLANPSR1MDM2CES2 | |
| SCHEMBL8530967 | 0.82 | GLA (0.46) | GLANPSR1CES2EP300CTRB1 | |
| SCHEMBL15647719 | 0.82 | GLA (0.67) | GLANPSR1MDM2 | |
| SCHEMBL16460894 | 0.82 | GLA (0.67) | GLANPSR1MDM2CES2TSHR | |
| SCHEMBL15570301 | 0.82 | GLA (0.67) | GLANPSR1MDM2CES2HTT | |
| SCHEMBL16174944 | 0.82 | GLA (0.46) | GLANPSR1CES2EP300CTRB1 | |
| SCHEMBL16174891 | 0.81 | GLA (0.45) | GLANPSR1EP300CTRB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039291-A | Enalidomide intermediate and preparation method thereof | 南京药坦生物科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20230255200-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | BASF SE (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| WO-2020247605-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247605-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-9611410-B2 | Adhesive resin composition, laminate, and self-stripping method | MITSUI CHEMICALS TOHCELLO, INC. (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160370523-A1 | POLARIZING PLATE COMPOSITION, POLARIZING PLATE PROTECTIVE FILM, POLARIZER, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-20160370523-A1 | POLARIZING PLATE COMPOSITION, POLARIZING PLATE PROTECTIVE FILM, POLARIZER, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9507067-B2 | Polarizing plate and liquid crystal display device including the same | FUJIFILM CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9507067-B2 | Polarizing plate and liquid crystal display device including the same | FUJIFILM CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-8795539-B2 | Block copolymer and method of forming patterns by using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-08-05 | — | — | US | disclosed |
| US-20120080404-A1 | BLOCK COPOLYMER AND METHOD OF FORMING PATTERNS BY USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-04-05 | — | — | US | disclosed |
| US-20120080404-A1 | BLOCK COPOLYMER AND METHOD OF FORMING PATTERNS BY USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-04-05 | — | — | US | disclosed |
| US-20100323964-A1 | NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES | ITALFARMACO SPA (IT) | 2010-12-23 | — | — | US | disclosed |
| US-5438118-A | Peptide mimics having constrained peptide backbone | SMITHKLINE BEECHMAN CORP. (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0578849-B1 | Process for the preparation of 1,3-dioxane-4,6-dione derivates | BIOGAL GYOGYSZERGYAR (HU) | 1995-05-17 | — | — | EP | disclosed |
| EP-0559793-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0578849-A1 | Process for the preparation of 1,3-dioxane-4,6-dione derivates | BIOGAL GYOGYSZERGYAR (HU) | 1994-01-19 | — | — | EP | disclosed |
| EP-0559793-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009297-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | NSUN3, TARBP1, TRDMT1 | GLA 1992/4885NPSR1 3206/4885MDM2 2753/4885 |
| US-20100323964-A1 | NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES | SSTR4, SSTR1, SSTR3 | GLA 2323/4885NPSR1 37/4885MDM2 4719/4885 |
| US-20230255200-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI | COX5B, SQOR, COX6B1 | GLA 3342/4885NPSR1 3082/4885MDM2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.